# Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

> **NCT01698905** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 163 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT01698905
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2015-11-26
- **Final completion:** 2025-01-29
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01698905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01698905, "Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01698905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*